Anne Gaml-Sørensen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anne Gaml-Sørensen has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
Nis Brix
Department of Public Health, Research Unit for Epidemiology, Bartholins Allé 2, Aarhus University, 8000, Aarhus, C, Denmark; Department of Clinical Genetics, Aarhus University Hospital, Brendstrupgårdsvej 21 C, 8200, Aarhus, N, Denmark
18 shared publications- Cecilia Høst Ramlau-Hansen
Department of Public Health, Research Unit for Epidemiology, Aarhus University, Aarhus, Denmark
14 shared publications - Sandra Søgaard Tøttenborg
Department of Occupational and Environmental Medicine, Copenhagen University Hospital–Bispebjerg and Frederiksberg, Copenhagen, Denmark
13 shared publications Gunnar Toft
Steno Diabetes Center Aarhus Aarhus University Hospital Aarhus Denmark
12 shared publicationsAndreas Ernst
Department of Public Health, Research Unit for Epidemiology, Bartholins Allé 2, Aarhus University, 8000, Aarhus, C, Denmark; Department of Urology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 35, 8200, Aarhus, N, Denmark
11 shared publicationsCecilia Høst Ramlau-Hansen
Department of Public Health, Research Unit for Epidemiology, Bartholins Allé 2, Aarhus University, 8000, Aarhus, C, Denmark
9 shared publications
Latest Publications
- Open Access
- 29 July 2026
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 41 (9) , 1602-1611
Body fat percentage in relation to semen characteristics, testicular volume, and reproductive hormones: a cross-sectional study
STUDY QUESTION: Is body fat percentage associated with semen characteristics, testicular volume, and reproductive hormone levels? SUMMARY ANSWER: Higher body fat percentage was associated with poor semen characteristics and impaired reproductive hormone levels but not with testicular volume. WHAT IS KNOWN ALREADY: High BMI is associated with poor semen characteristics and impaired reproductive hormone levels. However, it remains unsettled whether body fat percentage is related to semen characteristics, testicular volume, and hormone levels; whether body fat percentage is a better measure of adiposity than BMI and waist-to-height ratio and hence stronger associated with semen characteristics, testicular volume, and reproductive hormones; and whether a high body fat percentage is associated with semen characteristics, testicular volume, and reproductive hormones, even among men considered normal weight according to BMI. STUDY DESIGN, SIZE, DURATION: In this cross-sectional study, we used data from the Fetal Programming of Semen Quality (FEPOS) Cohort nested within the Danish National Birth Cohort. During 2017–2019, 1058 (19%) of 5697 invited men participated in FEPOS at the age of 18 years and 9 months. PARTICIPANTS/MATERIALS, SETTING, METHODS: The participants had their body fat percentage measured by bioelectrical impedance and had measured their BMI and waist-to-height ratio. They provided a semen and a blood sample, self-measured their testicular volume, and filled in a questionnaire on health behavior. Body fat percentage was analyzed as categories (<8%[low], 8–19% [normal, reference], 20–24% [high], ≥25% [very high]) and as a linear variable (in SDs). Relative differences in the outcomes in percent (with 95% confidence intervals) were estimated using negative binomial regression models. We further explored whether body fat percentage was stronger associated with impaired male fecundity than BMI and waist-to-height ratio, and whether an association for body fat percentage was present even among men considered normal weight according to BMI (BMI 18.5–24.9 kg/m2). MAIN RESULTS AND THE ROLE OF CHANCE: Compared to normal body fat percentage (8–19%), high (20–24%) and very high (≥25%) body fat percentages were associated with lower total sperm count (high: −23% [−35%, −9%]; very high: −15% [−35%, 13%]; continuous, per SD-increase in BMI: −8% [−13%, −2%]), and tendencies toward lower semen volume and concentration were observed. No associations were observed for the remaining semen characteristics and testicular volume. A higher body fat percentage was associated with lower sex hormone-binding globulin and testosterone levels, and higher free androgen index, LH, and estradiol levels. The results for low body fat (<8%) were generally in the opposite direction but less consistent. The associations with total sperm count, semen volume, and semen concentration were stronger for body fat percentage than for BMI and waist-to-height ratio. Further, the associations for body fat percentage with total sperm count and poorer normal morphology were even stronger among men considered normal weight according to BMI, although the associations for the reproductive hormones attenuated. LIMITATIONS, REASONS FOR CAUTION: The participation rate was low (19%) in FEPOS, which we tried to counter with selection weights. Even though body fat percentage measured by bioelectrical impedance constitutes a better measure of body fat than BMI, there may be misclassification. Data were collected cross-sectionally, which poses a risk of reverse causation. However, a sensitivity analysis using BMI at 11 years of age as the exposure indicated minimal risk of reverse causation. WIDER IMPLICATIONS OF THE FINDINGS: If our associations reflect causality, they suggest that a higher percentage of adipose tissue might adversely affect semen production and hormonal balance. FUNDING: This article is part of the ReproUnion collaborative study, co-financed by the European Union, Interreg V ÖKS (20200407). The FEPOS project was further funded by the Lundbeck Foundation (R170-2014-855), the Capital Region of Denmark, Medical doctor Sofus Carl Emil Friis and spouse Olga Doris Friis’s Grant, Axel Muusfeldt’s Foundation (2016-491), and A.P. Møller Foundation (16-37). This project was funded by the Independent Research Fund Denmark (grant no. 9039-00128B) and co-funded by the European Union (ERC, BIOSFER, 101071773). Views and opinions expressed herein are, however, those of the author(s) only and do not necessarily reflect those of the European Union or the European Research Council. Neither the European Union nor the granting authority can be held responsible for them. DISCLOSURES: K.S.H. declared to have Eli Lilly and Norvo Nordisk stocks. The remaining authors have no conflicts of interest. TRIAL REGISTRATION NUMBER: N/A.
- 29 July 2026
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 41 (9) , 1602-1611
Open AccessBody fat percentage in relation to semen characteristics, testicular volume, and reproductive hormones: a cross-sectional study
STUDY QUESTION: Is body fat percentage associated with semen characteristics, testicular volume, and reproductive hormone levels? SUMMARY ANSWER: Higher body fat percentage was associated with poor semen characteristics and impaired reproductive hormone levels but not with testicular volume. WHAT IS KNOWN ALREADY: High BMI is associated with poor semen characteristics and impaired reproductive hormone levels. However, it remains unsettled whether body fat percentage is related to semen characteristics, testicular volume, and hormone levels; whether body fat percentage is a better measure of adiposity than BMI and waist-to-height ratio and hence stronger associated with semen characteristics, testicular volume, and reproductive hormones; and whether a high body fat percentage is associated with semen characteristics, testicular volume, and reproductive hormones, even among men considered normal weight according to BMI. STUDY DESIGN, SIZE, DURATION: In this cross-sectional study, we used data from the Fetal Programming of Semen Quality (FEPOS) Cohort nested within the Danish National Birth Cohort. During 2017–2019, 1058 (19%) of 5697 invited men participated in FEPOS at the age of 18 years and 9 months. PARTICIPANTS/MATERIALS, SETTING, METHODS: The participants had their body fat percentage measured by bioelectrical impedance and had measured their BMI and waist-to-height ratio. They provided a semen and a blood sample, self-measured their testicular volume, and filled in a questionnaire on health behavior. Body fat percentage was analyzed as categories (<8%[low], 8–19% [normal, reference], 20–24% [high], ≥25% [very high]) and as a linear variable (in SDs). Relative differences in the outcomes in percent (with 95% confidence intervals) were estimated using negative binomial regression models. We further explored whether body fat percentage was stronger associated with impaired male fecundity than BMI and waist-to-height ratio, and whether an association for body fat percentage was present even among men considered normal weight according to BMI (BMI 18.5–24.9 kg/m2). MAIN RESULTS AND THE ROLE OF CHANCE: Compared to normal body fat percentage (8–19%), high (20–24%) and very high (≥25%) body fat percentages were associated with lower total sperm count (high: −23% [−35%, −9%]; very high: −15% [−35%, 13%]; continuous, per SD-increase in BMI: −8% [−13%, −2%]), and tendencies toward lower semen volume and concentration were observed. No associations were observed for the remaining semen characteristics and testicular volume. A higher body fat percentage was associated with lower sex hormone-binding globulin and testosterone levels, and higher free androgen index, LH, and estradiol levels. The results for low body fat (<8%) were generally in the opposite direction but less consistent. The associations with total sperm count, semen volume, and semen concentration were stronger for body fat percentage than for BMI and waist-to-height ratio. Further, the associations for body fat percentage with total sperm count and poorer normal morphology were even stronger among men considered normal weight according to BMI, although the associations for the reproductive hormones attenuated. LIMITATIONS, REASONS FOR CAUTION: The participation rate was low (19%) in FEPOS, which we tried to counter with selection weights. Even though body fat percentage measured by bioelectrical impedance constitutes a better measure of body fat than BMI, there may be misclassification. Data were collected cross-sectionally, which poses a risk of reverse causation. However, a sensitivity analysis using BMI at 11 years of age as the exposure indicated minimal risk of reverse causation. WIDER IMPLICATIONS OF THE FINDINGS: If our associations reflect causality, they suggest that a higher percentage of adipose tissue might adversely affect semen production and hormonal balance. FUNDING: This article is part of the ReproUnion collaborative study, co-financed by the European Union, Interreg V ÖKS (20200407). The FEPOS project was further funded by the Lundbeck Foundation (R170-2014-855), the Capital Region of Denmark, Medical doctor Sofus Carl Emil Friis and spouse Olga Doris Friis’s Grant, Axel Muusfeldt’s Foundation (2016-491), and A.P. Møller Foundation (16-37). This project was funded by the Independent Research Fund Denmark (grant no. 9039-00128B) and co-funded by the European Union (ERC, BIOSFER, 101071773). Views and opinions expressed herein are, however, those of the author(s) only and do not necessarily reflect those of the European Union or the European Research Council. Neither the European Union nor the granting authority can be held responsible for them. DISCLOSURES: K.S.H. declared to have Eli Lilly and Norvo Nordisk stocks. The remaining authors have no conflicts of interest. TRIAL REGISTRATION NUMBER: N/A.
- Open Access
Maternal Consumption of Artificially Sweetened Beverages in Pregnancies and Biomarkers of Fecundity in Adult Sons
Introduction: Maternal intake of artificial sweeteners in beverages (ASB) during pregnancy may have a programming effect on offspring health, including biomarkers of male fecundity. Objective: We investigated whether maternal intake of ASB during pregnancy was associated with biomarkers of male fecundity in adult sons. Materials and methods: In this cohort study, 880 young men from the Fetal Programming of Semen Quality cohort, nested within the Danish National Birth Cohort, were included. Information on maternal intake of ASB was collected via a food frequency questionnaire around gestational week 25 and categorized as: never, <1 serving/week, 1–<7 servings/week, and ≥1 serving/day. Outcomes included semen characteristics, average testicular volume, and reproductive hormone levels, collected at ages 18–21 years. A negative binomial regression model was applied to estimate relative differences (%) with 95% CIs in biomarkers by maternal ASB intake. Sensitivity, mediation, substitution, and dose‐response analyses tested robustness and explored potential pathways. Results: We observed no consistent associations between maternal ASB intake and most biomarkers of male fecundity. Sons of mothers consuming ≥1 serving/day showed higher levels of spermatozoa with immature chromatin structure (18.1%; 95% CI: 3.8, 34.3) and a tendency toward higher DNA fragmentation (6.8%; 95% CI: −5.4, 20.5) compared with unexposed sons. Maternal ASB intake was not associated with testes volume or reproductive hormone levels. Conclusion: Our results showed subtle adverse tendencies in specific biomarkers of male fecundity in adult sons of mothers who consumed artificially sweetened beverages during pregnancy. These include lower sperm concentration, lower proportion of normal sperm morphology, and higher proportions of spermatozoa with immature chromatin structure and DNA fragmentation, showing some of the same tendencies as observed in animal studies, suggesting sweeteners may affect sperm DNA. However, findings are uncertain and do not indicate clear adverse effects.
Open AccessMaternal Consumption of Artificially Sweetened Beverages in Pregnancies and Biomarkers of Fecundity in Adult Sons
Introduction: Maternal intake of artificial sweeteners in beverages (ASB) during pregnancy may have a programming effect on offspring health, including biomarkers of male fecundity. Objective: We investigated whether maternal intake of ASB during pregnancy was associated with biomarkers of male fecundity in adult sons. Materials and methods: In this cohort study, 880 young men from the Fetal Programming of Semen Quality cohort, nested within the Danish National Birth Cohort, were included. Information on maternal intake of ASB was collected via a food frequency questionnaire around gestational week 25 and categorized as: never, <1 serving/week, 1–<7 servings/week, and ≥1 serving/day. Outcomes included semen characteristics, average testicular volume, and reproductive hormone levels, collected at ages 18–21 years. A negative binomial regression model was applied to estimate relative differences (%) with 95% CIs in biomarkers by maternal ASB intake. Sensitivity, mediation, substitution, and dose‐response analyses tested robustness and explored potential pathways. Results: We observed no consistent associations between maternal ASB intake and most biomarkers of male fecundity. Sons of mothers consuming ≥1 serving/day showed higher levels of spermatozoa with immature chromatin structure (18.1%; 95% CI: 3.8, 34.3) and a tendency toward higher DNA fragmentation (6.8%; 95% CI: −5.4, 20.5) compared with unexposed sons. Maternal ASB intake was not associated with testes volume or reproductive hormone levels. Conclusion: Our results showed subtle adverse tendencies in specific biomarkers of male fecundity in adult sons of mothers who consumed artificially sweetened beverages during pregnancy. These include lower sperm concentration, lower proportion of normal sperm morphology, and higher proportions of spermatozoa with immature chromatin structure and DNA fragmentation, showing some of the same tendencies as observed in animal studies, suggesting sweeteners may affect sperm DNA. However, findings are uncertain and do not indicate clear adverse effects.
- Open Access
- 26 December 2025
- Published by Elsevier in Journal of Affective Disorders
- Vol. 398, 121014
Pubertal development and mental health: A population-based cohort study on self-rated health, psychotropic medication, and psychiatric diagnoses
- 26 December 2025
- Published by Elsevier in Journal of Affective Disorders
- Vol. 398, 121014
Open AccessPubertal development and mental health: A population-based cohort study on self-rated health, psychotropic medication, and psychiatric diagnoses
- Open Access
- 8 December 2025
- Published by Oxford University Press (OUP) in Human Reproduction Open
- Vol. 2026 (1) , hoaf077
Atopic dermatitis and fecundity: a Danish National Birth Cohort study
STUDY QUESTION: Do women with atopic dermatitis have higher fecundity than those without? SUMMARY ANSWER: Pregnant women with a history of atopic dermatitis had a slightly shorter time-to-pregnancy (TTP) and a lower risk of conceiving using infertility treatment than those without. WHAT IS KNOWN ALREADY: Atopic dermatitis has a characteristic T-helper-2-cell-skewed immune response that mirrors the immune shift in pregnancy, which is necessary for the pregnant woman’s immune response to tolerate the fetus. Therefore, it has been hypothesized that atopic dermatitis may be advantageous for conception and pregnancy maintenance. However, this has not yet been investigated. STUDY DESIGN, SIZE, DURATION: This cohort study included 88 713 pregnant women from the population-based Danish National Birth Cohort (DNBC), who were enrolled between 1996 and 2002. PARTICIPANTS/MATERIALS, SETTING, METHODS: The women were defined as having atopic dermatitis if, in a computer-assisted interview conducted around gestational week 17, they reported having ever been diagnosed with atopic dermatitis by a doctor. The women were also asked whether the pregnancy was planned or unplanned, to report their TTP within one of five prespecified categories, and whether they had conceived with the use of infertility treatment. We used multinomial logistic regression models to assess associations between atopic dermatitis and fecundity in seven categories: (TTP 12 months, pregnant after infertility treatment or unplanned). In addition, we modeled TTP as dichotomous outcomes using logistic regression: subfecundity (TTP ≥6 months vs 12 months vs ≤12 months). We also assessed women with an atopic constitution (atopic dermatitis, allergic rhinitis, asthma, and food allergies), as this is associated with more severe atopic dermatitis. MAIN RESULTS AND THE ROLE OF CHANCE: Overall, 3641 (4.1%) women reported ever having had atopic dermatitis. Compared to women without atopic dermatitis, women with atopic dermatitis had a lower relative risk ratio (RRR) of having a TTP >12 months: 0.83 (95% CI: 0.72; 0.96), and use of infertility treatment, RRR: 0.81 (95% CI: 0.69; 0.94). Moreover, women with atopic dermatitis had a lower odds ratio (OR) of subfecundity: 0.89 (95% CI: 0.82; 0.96) and infertility: 0.85 (95% CI: 0.77; 0.95) than women without in the logistic regression model. Results were robust across several sub-analyses. LIMITATIONS, REASONS FOR CAUTION: The results can only be generalized to women who eventually conceive, since the DNBC consists only of women who successfully conceived. WIDER IMPLICATIONS OF THE FINDINGS: The findings support the hypothesis of an immunological benefit in conceiving when having atopic dermatitis. The results are reassuring for women with atopic dermatitis trying to conceive. However, the hypothesis should be further tested in a broader population of women without conditioning on pregnancy. STUDY FUNDING/COMPETING INTEREST(S): The work was supported by the Danish Council for Independent Research (grant number DFF—1030-00164B), Aarhus University, and Fonden af Fam. Kjærsgaard, Sunds, the Research Council of Norway (project no. 320656), through its Centres of Excellence funding scheme (project no. 262700), and co-funded by the European Union (ERC, BIOSFER, 101071773). However, views and opinions expressed herein are those of the author(s) only and do not necessarily reflect those of the European Union or the European Research Council. Neither the European Union nor the granting authority can be held responsible. This publication is part of the ReproUnion collaborative study, co-financed by the European Union, Intereg V ÖKS (20200407). M.D. has received consulting fees (including participation on advisory boards) from AbbVie, LEO Pharma, Eli Lilly, Incyte, La Roche Posay, NUMAB Therapeutics, Pfizer, Regeneron Pharmaceuticals Inc., Sanofi Genzyme, Almirall, Union Therapeutics, Kymab, and UCB; travel support from LEO Pharma and Sanofi Genzyme; speaker fees from Mustela, Galderma, Leo Pharma, Sanofi Genzyme, and La Roche Posay; Section editor for Journal of the European Academy of Dermatology and Venereology (JEADV). None of these COIs is relevant to the present article. The remaining authors declare that they have no conflicts of interest. TRIAL REGISTRATION NUMBER: N/A.
- 8 December 2025
- Published by Oxford University Press (OUP) in Human Reproduction Open
- Vol. 2026 (1) , hoaf077
Open AccessAtopic dermatitis and fecundity: a Danish National Birth Cohort study
STUDY QUESTION: Do women with atopic dermatitis have higher fecundity than those without? SUMMARY ANSWER: Pregnant women with a history of atopic dermatitis had a slightly shorter time-to-pregnancy (TTP) and a lower risk of conceiving using infertility treatment than those without. WHAT IS KNOWN ALREADY: Atopic dermatitis has a characteristic T-helper-2-cell-skewed immune response that mirrors the immune shift in pregnancy, which is necessary for the pregnant woman’s immune response to tolerate the fetus. Therefore, it has been hypothesized that atopic dermatitis may be advantageous for conception and pregnancy maintenance. However, this has not yet been investigated. STUDY DESIGN, SIZE, DURATION: This cohort study included 88 713 pregnant women from the population-based Danish National Birth Cohort (DNBC), who were enrolled between 1996 and 2002. PARTICIPANTS/MATERIALS, SETTING, METHODS: The women were defined as having atopic dermatitis if, in a computer-assisted interview conducted around gestational week 17, they reported having ever been diagnosed with atopic dermatitis by a doctor. The women were also asked whether the pregnancy was planned or unplanned, to report their TTP within one of five prespecified categories, and whether they had conceived with the use of infertility treatment. We used multinomial logistic regression models to assess associations between atopic dermatitis and fecundity in seven categories: (TTP 12 months, pregnant after infertility treatment or unplanned). In addition, we modeled TTP as dichotomous outcomes using logistic regression: subfecundity (TTP ≥6 months vs 12 months vs ≤12 months). We also assessed women with an atopic constitution (atopic dermatitis, allergic rhinitis, asthma, and food allergies), as this is associated with more severe atopic dermatitis. MAIN RESULTS AND THE ROLE OF CHANCE: Overall, 3641 (4.1%) women reported ever having had atopic dermatitis. Compared to women without atopic dermatitis, women with atopic dermatitis had a lower relative risk ratio (RRR) of having a TTP >12 months: 0.83 (95% CI: 0.72; 0.96), and use of infertility treatment, RRR: 0.81 (95% CI: 0.69; 0.94). Moreover, women with atopic dermatitis had a lower odds ratio (OR) of subfecundity: 0.89 (95% CI: 0.82; 0.96) and infertility: 0.85 (95% CI: 0.77; 0.95) than women without in the logistic regression model. Results were robust across several sub-analyses. LIMITATIONS, REASONS FOR CAUTION: The results can only be generalized to women who eventually conceive, since the DNBC consists only of women who successfully conceived. WIDER IMPLICATIONS OF THE FINDINGS: The findings support the hypothesis of an immunological benefit in conceiving when having atopic dermatitis. The results are reassuring for women with atopic dermatitis trying to conceive. However, the hypothesis should be further tested in a broader population of women without conditioning on pregnancy. STUDY FUNDING/COMPETING INTEREST(S): The work was supported by the Danish Council for Independent Research (grant number DFF—1030-00164B), Aarhus University, and Fonden af Fam. Kjærsgaard, Sunds, the Research Council of Norway (project no. 320656), through its Centres of Excellence funding scheme (project no. 262700), and co-funded by the European Union (ERC, BIOSFER, 101071773). However, views and opinions expressed herein are those of the author(s) only and do not necessarily reflect those of the European Union or the European Research Council. Neither the European Union nor the granting authority can be held responsible. This publication is part of the ReproUnion collaborative study, co-financed by the European Union, Intereg V ÖKS (20200407). M.D. has received consulting fees (including participation on advisory boards) from AbbVie, LEO Pharma, Eli Lilly, Incyte, La Roche Posay, NUMAB Therapeutics, Pfizer, Regeneron Pharmaceuticals Inc., Sanofi Genzyme, Almirall, Union Therapeutics, Kymab, and UCB; travel support from LEO Pharma and Sanofi Genzyme; speaker fees from Mustela, Galderma, Leo Pharma, Sanofi Genzyme, and La Roche Posay; Section editor for Journal of the European Academy of Dermatology and Venereology (JEADV). None of these COIs is relevant to the present article. The remaining authors declare that they have no conflicts of interest. TRIAL REGISTRATION NUMBER: N/A.
- Open Access
- 22 September 2025
- Published by Oxford University Press (OUP) in Human Reproduction Open
- Vol. 2025 (4)
Timing and tempo of pubertal development and substance use in adolescence: a cohort study in the Danish National Birth Cohort
STUDY QUESTION: Are the age at reaching different pubertal milestones, and the tempo of pubertal progression, associated with cigarette smoking, alcohol intake, or recreational drug use in adolescence? SUMMARY ANSWER: Earlier age at pubertal development was associated with a higher risk of smoking cigarettes, drinking alcohol (only boys), and using recreational drugs in adolescence, and a faster tempo tended to be associated with higher risks, mainly in girls, while any associations in boys appeared less clear. WHAT IS KNOWN ALREADY: Girls and boys with an earlier age at pubertal development are suggested to have a higher risk of engaging in risk-taking behaviours, which include use of substances, primarily studied for smoking and alcohol. The potential impact of pubertal tempo has been studied less. STUDY DESIGN, SIZE, DURATION: In this cohort study, 8063 girls and boys born from 2000 to 2003 by mothers in the Danish National Birth Cohort participated. Information on covariates was obtained from pregnancy interviews and a follow-up questionnaire at age 7. Information on pubertal development was obtained from questionnaires completed by the girls and boys throughout puberty, starting at age 11, and information on substance use, covering cigarette smoking, alcohol, and recreational drug use, was obtained from a questionnaire completed at a mean age of 18 years and 4 months. PARTICIPANTS/MATERIALS, SETTING, METHODS: A multinomial logistic regression model was used to obtain adjusted relative risk ratios (RRRs) of smoking, drinking alcohol, and using recreational drugs (non-medical use of psychoactive substances) per 1 year earlier timing of pubertal development (Tanner stages of breast/genital and pubic hair development, menarche, first ejaculation, and voice break) and for tempo per one-unit (Tanner stages per year) faster tempo. Additionally, we also analysed categories of pubertal timing (15% earliest, 70% (ref.), 15% latest) and tempo (15% fastest, 70% (ref.), 15% slowest). The timing and tempo of the development of Tanner stages were derived using a non-linear mixed-effects model. MAIN RESULTS AND THE ROLE OF CHANCE: At the age of 18 years, 19% of girls and 20% of boys reported smoking at least monthly, 69% of girls and 71% of boys reported consuming alcohol more frequently than once a month, and 17% of girls and 30% of boys reported use of recreational drugs (primarily hash or pot) at some point during the past year. In girls, the RRR per 1-year earlier breast development was 1.20 (95% CI, 1.08–1.34) for smoking daily or weekly and 1.10 (95% CI, 0.97–1.25) for smoking monthly, and in boys, the RRR per 1-year earlier genital development was 1.09 (95% CI, 0.94–1.27) for smoking daily or weekly and 1.17 (95% CI, 1.02–1.34) for smoking monthly compared to no smoking. In girls, earlier age at menarche, but no other milestone, was associated with lower risk of alcohol consumption at age 18, whereas in boys, earlier age at genital development was associated with higher risk of drinking alcohol weekly (RRR 1.13 (95% CI, 0.99–1.30) per 1-year earlier timing) and 2–4 times/month (RRR 1.07 (95% CI, 0.96–1.19) per 1-year earlier timing) compared to drinking alcohol ≤1 time/month. In girls, the RRR per 1-year earlier breast development was 1.31 (95% CI, 1.07–1.59) for using recreational drugs monthly and 1.04 (95% CI, 0.93–1.15) for using recreational drugs <1 time/month. In boys, the RRR per 1-year earlier genital development was 1.17 (95% CI, 0.97–1.43) for using recreational drugs monthly and 1.16 (95% CI, 1.03–1.30) for using recreational drugs <1 time/month compared to no recreational drug use. Faster pubertal tempo tended to be associated with higher risk of smoking, drinking alcohol, and using recreational drugs, mainly in girls. LIMITATIONS, REASONS FOR CAUTION: Information on pubertal development was self-reported, introducing a risk of misclassification of pubertal timing and tempo. Furthermore, the self-reported information on smoking habits, alcohol intake, and recreational drug use might be under-reported due to social stigmatization. We were not able to explore associations with snus or e-cigarettes, although this may be highly relevant. WIDER IMPLICATIONS OF THE FINDINGS: The findings suggest that girls and boys with earlier and maybe faster pubertal development may be high-risk groups for smoking cigarettes, drinking alcohol, and using recreational drugs. The associations were observed across various pubertal milestones, and the consistent findings across these strengthen the conclusion and support what has previously been shown primarily for pubertal timing and smoking. Our findings on pubertal tempo suggest that preventive strategies could benefit from targeting early developers and also fast-developing girls. This study was performed in a Danish cohort, and the findings are likely transferable to other Western populations with a comparable smoking, alcohol, and drug use culture. STUDY FUNDING/COMPETING INTEREST(S): This study has been supported by the Lundbeck Foundation (R396-2022-265). The project was further co-funded by the European Union (ERC, BIOSFER, 101071773). Views and opinions expressed are those of the author(s) only and do not necessarily reflect those of the European Union or the European Research Council. Neither the European Union nor the granting authority can be held responsible for them. The authors have no conflicts of interest to declare. TRIAL REGISTRATION NUMBER: N/A.
- 22 September 2025
- Published by Oxford University Press (OUP) in Human Reproduction Open
- Vol. 2025 (4)
Open AccessTiming and tempo of pubertal development and substance use in adolescence: a cohort study in the Danish National Birth Cohort
STUDY QUESTION: Are the age at reaching different pubertal milestones, and the tempo of pubertal progression, associated with cigarette smoking, alcohol intake, or recreational drug use in adolescence? SUMMARY ANSWER: Earlier age at pubertal development was associated with a higher risk of smoking cigarettes, drinking alcohol (only boys), and using recreational drugs in adolescence, and a faster tempo tended to be associated with higher risks, mainly in girls, while any associations in boys appeared less clear. WHAT IS KNOWN ALREADY: Girls and boys with an earlier age at pubertal development are suggested to have a higher risk of engaging in risk-taking behaviours, which include use of substances, primarily studied for smoking and alcohol. The potential impact of pubertal tempo has been studied less. STUDY DESIGN, SIZE, DURATION: In this cohort study, 8063 girls and boys born from 2000 to 2003 by mothers in the Danish National Birth Cohort participated. Information on covariates was obtained from pregnancy interviews and a follow-up questionnaire at age 7. Information on pubertal development was obtained from questionnaires completed by the girls and boys throughout puberty, starting at age 11, and information on substance use, covering cigarette smoking, alcohol, and recreational drug use, was obtained from a questionnaire completed at a mean age of 18 years and 4 months. PARTICIPANTS/MATERIALS, SETTING, METHODS: A multinomial logistic regression model was used to obtain adjusted relative risk ratios (RRRs) of smoking, drinking alcohol, and using recreational drugs (non-medical use of psychoactive substances) per 1 year earlier timing of pubertal development (Tanner stages of breast/genital and pubic hair development, menarche, first ejaculation, and voice break) and for tempo per one-unit (Tanner stages per year) faster tempo. Additionally, we also analysed categories of pubertal timing (15% earliest, 70% (ref.), 15% latest) and tempo (15% fastest, 70% (ref.), 15% slowest). The timing and tempo of the development of Tanner stages were derived using a non-linear mixed-effects model. MAIN RESULTS AND THE ROLE OF CHANCE: At the age of 18 years, 19% of girls and 20% of boys reported smoking at least monthly, 69% of girls and 71% of boys reported consuming alcohol more frequently than once a month, and 17% of girls and 30% of boys reported use of recreational drugs (primarily hash or pot) at some point during the past year. In girls, the RRR per 1-year earlier breast development was 1.20 (95% CI, 1.08–1.34) for smoking daily or weekly and 1.10 (95% CI, 0.97–1.25) for smoking monthly, and in boys, the RRR per 1-year earlier genital development was 1.09 (95% CI, 0.94–1.27) for smoking daily or weekly and 1.17 (95% CI, 1.02–1.34) for smoking monthly compared to no smoking. In girls, earlier age at menarche, but no other milestone, was associated with lower risk of alcohol consumption at age 18, whereas in boys, earlier age at genital development was associated with higher risk of drinking alcohol weekly (RRR 1.13 (95% CI, 0.99–1.30) per 1-year earlier timing) and 2–4 times/month (RRR 1.07 (95% CI, 0.96–1.19) per 1-year earlier timing) compared to drinking alcohol ≤1 time/month. In girls, the RRR per 1-year earlier breast development was 1.31 (95% CI, 1.07–1.59) for using recreational drugs monthly and 1.04 (95% CI, 0.93–1.15) for using recreational drugs <1 time/month. In boys, the RRR per 1-year earlier genital development was 1.17 (95% CI, 0.97–1.43) for using recreational drugs monthly and 1.16 (95% CI, 1.03–1.30) for using recreational drugs <1 time/month compared to no recreational drug use. Faster pubertal tempo tended to be associated with higher risk of smoking, drinking alcohol, and using recreational drugs, mainly in girls. LIMITATIONS, REASONS FOR CAUTION: Information on pubertal development was self-reported, introducing a risk of misclassification of pubertal timing and tempo. Furthermore, the self-reported information on smoking habits, alcohol intake, and recreational drug use might be under-reported due to social stigmatization. We were not able to explore associations with snus or e-cigarettes, although this may be highly relevant. WIDER IMPLICATIONS OF THE FINDINGS: The findings suggest that girls and boys with earlier and maybe faster pubertal development may be high-risk groups for smoking cigarettes, drinking alcohol, and using recreational drugs. The associations were observed across various pubertal milestones, and the consistent findings across these strengthen the conclusion and support what has previously been shown primarily for pubertal timing and smoking. Our findings on pubertal tempo suggest that preventive strategies could benefit from targeting early developers and also fast-developing girls. This study was performed in a Danish cohort, and the findings are likely transferable to other Western populations with a comparable smoking, alcohol, and drug use culture. STUDY FUNDING/COMPETING INTEREST(S): This study has been supported by the Lundbeck Foundation (R396-2022-265). The project was further co-funded by the European Union (ERC, BIOSFER, 101071773). Views and opinions expressed are those of the author(s) only and do not necessarily reflect those of the European Union or the European Research Council. Neither the European Union nor the granting authority can be held responsible for them. The authors have no conflicts of interest to declare. TRIAL REGISTRATION NUMBER: N/A.
- Open Access
- 10 September 2025
- Published by Elsevier in Clinical Nutrition ESPEN
- Vol. 70, 18-28
Dietary quality in mid-pregnancy and pubertal timing in offspring: A population-based cohort study
- 10 September 2025
- Published by Elsevier in Clinical Nutrition ESPEN
- Vol. 70, 18-28
Open AccessDietary quality in mid-pregnancy and pubertal timing in offspring: A population-based cohort study
- Open Access
- 3 September 2025
- Published by Elsevier in Journal of Affective Disorders
- Vol. 392, 120179
Internalizing and externalizing symptoms and prosocial behavior and pubertal timing in boys and girls: A cohort study
- 3 September 2025
- Published by Elsevier in Journal of Affective Disorders
- Vol. 392, 120179
Open AccessInternalizing and externalizing symptoms and prosocial behavior and pubertal timing in boys and girls: A cohort study
- Open Access
Vitamin D levels and biomarkers of male fecundity: A study from the Danish National Birth Cohort
Background: Vitamin D is metabolised throughout the male reproductive system, suggesting a direct regulatory role of vitamin D in male reproduction. Objectives: To investigate the association between plasma vitamin D levels at sperm ejaculation and during spermatogenesis and biomarkers of male fecundity in young men. Materials and methods: From the Fetal Programming of Semen Quality cohort, Denmark, 2017–2019, 1047 young men provided a semen and a blood sample, and self‐measured their testes volume at a clinical visit. Plasma levels of vitamin D (25(OH)D 3 ) and reproductive hormones were measured in the blood sample. Relative percentage differences in semen characteristics, testes volume and reproductive hormone levels were analysed according to measured vitamin D levels (categorised, continuous and as restricted cubic splines) at sperm ejaculation. Additionally, we used the seasonal variation in endogenous vitamin D synthesis to estimate individual vitamin D levels 3 months prior to sperm ejaculation (at initiation of spermatogenesis) in addition to 2 and 1 month before. This was analysed following the same strategy. Results: Compared to measured vitamin D levels >75 nmol/L, levels <25 nmol/L at sperm ejaculation were associated with lower total sperm count (‒15% [95% confidence interval: ‒33%; 8%]), and a higher proportion of non‐progressive and immotile spermatozoa (11% [95% confidence interval: 0%; 24%]). Lower measured vitamin D levels were also associated with higher oestradiol, lower sex hormone‐binding globulin and lower follicle‐stimulating hormone, in dose‐dependent manners. Vitamin D levels estimated before and during spermatogenesis yielded similar associations as vitamin D levels measured at sperm ejaculation. Discussion: By using the seasonal variation in endogen vitamin D synthesis, we were able to estimate individual vitamin D levels during spermatogenesis. Conclusion: Lower vitamin D levels before and during spermatogenesis and at sperm ejaculation were associated with lower total sperm count and sperm motility and an altered reproductive hormone profile.
Open AccessVitamin D levels and biomarkers of male fecundity: A study from the Danish National Birth Cohort
Background: Vitamin D is metabolised throughout the male reproductive system, suggesting a direct regulatory role of vitamin D in male reproduction. Objectives: To investigate the association between plasma vitamin D levels at sperm ejaculation and during spermatogenesis and biomarkers of male fecundity in young men. Materials and methods: From the Fetal Programming of Semen Quality cohort, Denmark, 2017–2019, 1047 young men provided a semen and a blood sample, and self‐measured their testes volume at a clinical visit. Plasma levels of vitamin D (25(OH)D 3 ) and reproductive hormones were measured in the blood sample. Relative percentage differences in semen characteristics, testes volume and reproductive hormone levels were analysed according to measured vitamin D levels (categorised, continuous and as restricted cubic splines) at sperm ejaculation. Additionally, we used the seasonal variation in endogenous vitamin D synthesis to estimate individual vitamin D levels 3 months prior to sperm ejaculation (at initiation of spermatogenesis) in addition to 2 and 1 month before. This was analysed following the same strategy. Results: Compared to measured vitamin D levels >75 nmol/L, levels <25 nmol/L at sperm ejaculation were associated with lower total sperm count (‒15% [95% confidence interval: ‒33%; 8%]), and a higher proportion of non‐progressive and immotile spermatozoa (11% [95% confidence interval: 0%; 24%]). Lower measured vitamin D levels were also associated with higher oestradiol, lower sex hormone‐binding globulin and lower follicle‐stimulating hormone, in dose‐dependent manners. Vitamin D levels estimated before and during spermatogenesis yielded similar associations as vitamin D levels measured at sperm ejaculation. Discussion: By using the seasonal variation in endogen vitamin D synthesis, we were able to estimate individual vitamin D levels during spermatogenesis. Conclusion: Lower vitamin D levels before and during spermatogenesis and at sperm ejaculation were associated with lower total sperm count and sperm motility and an altered reproductive hormone profile.
- Open Access
Season of birth and variations in male reproductive health: A population‐based cohort study
Background: Season of birth has been associated with various later reproductive health outcomes in women, but little is known on the potential associations in men. Objectives: To investigate the association between season of birth and semen characteristics, testes volume and reproductive hormone levels in young men. Materials and methods: We conducted a follow‐up study of 1058 young men, born 1998 to 2000, from the Fetal Programming of Semen Quality (FEPOS) cohort, Denmark, 2017–2019. Information on season of birth was obtained from the Danish Civil Registration System, and information on male reproductive health outcomes was obtained at a clinical examination, where the men provided a semen and a blood sample and measured testes volume. Percentage differences in semen characteristics, testes volume and reproductive hormone levels were calculated according to season of birth (binary (main analysis): summer; winter and categorised by four calendar seasons and by calendar month (subanalyses)) using adjusted regression models and visualisalised according to month of birth. Results: Testosterone levels were lower (−3% (95% CI: −7%; 0%)) and oestradiol levels were higher (10% (95% CI: 2%; 20%)) in men born during the winter half‐year than the summer half‐year. The finding of higher oestradiol in men born during the winter was corroborated in analyses of calendar season and month of birth. Other reproductive health outcomes displayed some variation; however, estimates were generally close to null. Discussion: Although oestradiol levels seemed higher in men born during the winter half‐year, this could be a chance finding. Since pregnancies usually span three seasons, this finding could therefore also reflect an association between early pregnancy during the summer and oestradiol levels. Conclusion: We observed higher oestradiol levels in men born during the winter than during the summer half‐year. For the remaining reproductive health outcomes, the observed fluctuations may reflect random variation.
Open AccessSeason of birth and variations in male reproductive health: A population‐based cohort study
Background: Season of birth has been associated with various later reproductive health outcomes in women, but little is known on the potential associations in men. Objectives: To investigate the association between season of birth and semen characteristics, testes volume and reproductive hormone levels in young men. Materials and methods: We conducted a follow‐up study of 1058 young men, born 1998 to 2000, from the Fetal Programming of Semen Quality (FEPOS) cohort, Denmark, 2017–2019. Information on season of birth was obtained from the Danish Civil Registration System, and information on male reproductive health outcomes was obtained at a clinical examination, where the men provided a semen and a blood sample and measured testes volume. Percentage differences in semen characteristics, testes volume and reproductive hormone levels were calculated according to season of birth (binary (main analysis): summer; winter and categorised by four calendar seasons and by calendar month (subanalyses)) using adjusted regression models and visualisalised according to month of birth. Results: Testosterone levels were lower (−3% (95% CI: −7%; 0%)) and oestradiol levels were higher (10% (95% CI: 2%; 20%)) in men born during the winter half‐year than the summer half‐year. The finding of higher oestradiol in men born during the winter was corroborated in analyses of calendar season and month of birth. Other reproductive health outcomes displayed some variation; however, estimates were generally close to null. Discussion: Although oestradiol levels seemed higher in men born during the winter half‐year, this could be a chance finding. Since pregnancies usually span three seasons, this finding could therefore also reflect an association between early pregnancy during the summer and oestradiol levels. Conclusion: We observed higher oestradiol levels in men born during the winter than during the summer half‐year. For the remaining reproductive health outcomes, the observed fluctuations may reflect random variation.
- Open Access
- 21 March 2025
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 194 (8) , 2270-2280
Pubertal timing and tempo and body mass index trajectories: investigating the confounding role of childhood body mass index
Earlier pubertal timing and faster pubertal tempo (pace of progression through puberty) might be associated with increased body mass index (BMI) later in life. In a follow-up study of 13 219 boys and girls from the Danish National Birth Cohort, we investigated the association between pubertal timing and tempo and BMI trajectories from puberty to adulthood and explored the potential confounding role of childhood BMI. Based on half-yearly information on self-reported current Tanner stages, pubertal timing and tempo were estimated using nonlinear mixed-effect growth models. In total, 136 457 height and weight measurements from 7 to 18 years were included. BMI trajectories from 11 to 18 years were fitted according to pubertal timing and tempo while adjusting for potential confounders, including childhood BMI at age 7 years. Children with earlier pubertal timing had higher and children with later pubertal timing had lower BMI trajectories from 11 to 18 years than children with average pubertal timing. After adjustment for childhood BMI, the difference disappeared in boys but persisted in girls, suggesting that earlier pubertal timing may be independently associated with later BMI in girls only. Faster pubertal tempo was associated with slightly higher BMI in young women only.
- 21 March 2025
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 194 (8) , 2270-2280
Open AccessPubertal timing and tempo and body mass index trajectories: investigating the confounding role of childhood body mass index
Earlier pubertal timing and faster pubertal tempo (pace of progression through puberty) might be associated with increased body mass index (BMI) later in life. In a follow-up study of 13 219 boys and girls from the Danish National Birth Cohort, we investigated the association between pubertal timing and tempo and BMI trajectories from puberty to adulthood and explored the potential confounding role of childhood BMI. Based on half-yearly information on self-reported current Tanner stages, pubertal timing and tempo were estimated using nonlinear mixed-effect growth models. In total, 136 457 height and weight measurements from 7 to 18 years were included. BMI trajectories from 11 to 18 years were fitted according to pubertal timing and tempo while adjusting for potential confounders, including childhood BMI at age 7 years. Children with earlier pubertal timing had higher and children with later pubertal timing had lower BMI trajectories from 11 to 18 years than children with average pubertal timing. After adjustment for childhood BMI, the difference disappeared in boys but persisted in girls, suggesting that earlier pubertal timing may be independently associated with later BMI in girls only. Faster pubertal tempo was associated with slightly higher BMI in young women only.